- REGENXBIO to Participate in Upcoming Investor Conferences
- REGENXBIO Reports First Quarter 2024 Financial Results and Recent Operational Highlights
- REGENXBIO to Host Conference Call on May 8 to Discuss First Quarter 2024 Financial Results and Recent Operational Highlights
- REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
- REGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD
- REGENXBIO to Participate in Cantor Fitzgerald's Virtual DMD and Other Dystrophy Days
- REGENXBIO Announces Pricing of Upsized Public Offering of Common Stock and Pre-funded Warrants
- REGENXBIO Announces Proposed Public Offering of Common Stock
- REGENXBIO ANNOUNCES NEW POSITIVE INITIAL EFFICACY DATA FROM AFFINITY DUCHENNE® TRIAL
- REGENXBIO to Host Webcast Event to Discuss New Interim Clinical Data from the Phase I/II AFFINITY DUCHENNE® Trial
More ▼
Key statistics
On Thursday, Regenxbio Inc (RGNX:NSQ) closed at 14.96, 26.46% above the 52 week low of 11.83 set on Feb 02, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 15.52 |
---|---|
High | 15.91 |
Low | 14.76 |
Bid | 14.50 |
Offer | 17.00 |
Previous close | 15.47 |
Average volume | 390.42k |
---|---|
Shares outstanding | 49.26m |
Free float | 45.74m |
P/E (TTM) | -- |
Market cap | 761.99m USD |
EPS (TTM) | -5.88 USD |
Data delayed at least 15 minutes, as of May 23 2024 21:00 BST.
More ▼